NATCO Pharma has posted its financial results for the first quarter ended June 30, 2025, reporting a consolidated total revenue of ₹1,390.6 crore, down slightly from ₹1,410.7 crore in the same period last year. The company recorded an EBITDA of ₹632.7 crore, translating to strong margins of 45.5%. Consolidated net profit for the quarter stood at ₹480.3 crore, marking a 28.1% decline from ₹668 crore in Q1 FY25.
The quarter was marked by pricing pressure in the US product portfolio and higher R&D expenses, with the company investing in high-value projects to strengthen its pipeline. Despite these challenges, NATCO Pharma’s Board of Directors has announced an interim dividend of ₹2 per equity share of face value ₹2 each for Q1 FY26.
Segment-wise Performance
-
Active Pharmaceutical Ingredients (API): ₹52.6 crore in Q1 FY26, up from ₹39.2 crore in Q1 FY25.
-
Domestic Formulations: ₹107 crore, compared to ₹102.2 crore last year.
-
Formulations Export (Including profit share and subsidiaries): ₹1,126.5 crore, down from ₹1,210.1 crore in the year-ago quarter.
-
Crop Health Sciences (CHS): ₹34.7 crore, more than double last year’s ₹15.6 crore.
-
Other Income: ₹69.8 crore, higher than ₹43.6 crore in Q1 FY25.
Sequentially, the company’s total revenue rose from ₹1,287.3 crore in Q4 FY25 to ₹1,390.6 crore in Q1 FY26, reflecting growth across most business segments except exports, which saw a YoY decline.
